155 related articles for article (PubMed ID: 37855991)
1. Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma.
Wang N; Mo Z; Pan L; Zhou M; Ye X; Liu X; Cai X; Qian C; Chen F; Xiong Y; Fan F; Li W
Target Oncol; 2023 Nov; 18(6):941-952. PubMed ID: 37855991
[TBL] [Abstract][Full Text] [Related]
2. A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy.
Fan F; Liu P; Bao R; Chen J; Zhou M; Mo Z; Ma Y; Liu H; Zhou Y; Cai X; Qian C; Liu X
Cancer Res; 2021 Dec; 81(24):6233-6245. PubMed ID: 34711611
[TBL] [Abstract][Full Text] [Related]
3. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
Li J; Qian C; Zhou Q; Li J; Li K; Yi P
Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity and pharmacologic characterization of the depsipeptide analog as a novel histone deacetylase/ phosphatidylinositol 3-kinase dual inhibitor.
Saijo K; Imai H; Chikamatsu S; Narita K; Katoh T; Ishioka C
Cancer Sci; 2017 Jul; 108(7):1469-1475. PubMed ID: 28406576
[TBL] [Abstract][Full Text] [Related]
5. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
Zhang K; Huang L; Lai F; Lin S; Tian H; Wu D; Chen X; Xu H
Bioorg Med Chem Lett; 2022 Sep; 71():128825. PubMed ID: 35644299
[TBL] [Abstract][Full Text] [Related]
6. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
Ma L; Bian X; Lin W
J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
[TBL] [Abstract][Full Text] [Related]
7. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
[TBL] [Abstract][Full Text] [Related]
8. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
Mondello P; Derenzini E; Asgari Z; Philip J; Brea EJ; Seshan V; Hendrickson RC; de Stanchina E; Scheinberg DA; Younes A
Oncotarget; 2017 Feb; 8(8):14017-14028. PubMed ID: 28147336
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC.
Wu CH; Yang CY; Wang L; Gao HX; Rakhshandehroo T; Afghani S; Pincus L; Balassanian R; Rubenstein J; Gill R; Bandyopadhyay S; McCormick F; Moasser M; Ai WZ
J Invest Dermatol; 2021 Feb; 141(2):364-373. PubMed ID: 32603749
[TBL] [Abstract][Full Text] [Related]
11. LPIN1 downregulation enhances anticancer activity of the novel HDAC/PI3K dual inhibitor FK-A11.
Imai H; Saijo K; Chikamatsu S; Kawamura Y; Ishioka C
Cancer Sci; 2021 Feb; 112(2):792-802. PubMed ID: 33274548
[TBL] [Abstract][Full Text] [Related]
12. The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis.
Zhang X; Wu Y; Sun X; Cui Q; Bai X; Dong G; Gao Z; Wang Y; Gao C; Sun S; Ji N; Liu Y
BMC Cancer; 2022 Feb; 22(1):190. PubMed ID: 35184749
[TBL] [Abstract][Full Text] [Related]
13. Discovery of Novel Janus Kinase (JAK) and Histone Deacetylase (HDAC) Dual Inhibitors for the Treatment of Hematological Malignancies.
Liang X; Zang J; Li X; Tang S; Huang M; Geng M; Chou CJ; Li C; Cao Y; Xu W; Liu H; Zhang Y
J Med Chem; 2019 Apr; 62(8):3898-3923. PubMed ID: 30901208
[TBL] [Abstract][Full Text] [Related]
14. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
[TBL] [Abstract][Full Text] [Related]
16. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
[TBL] [Abstract][Full Text] [Related]
17. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
[TBL] [Abstract][Full Text] [Related]
18. HDAC Inhibition Enhances the
Faião-Flores F; Emmons MF; Durante MA; Kinose F; Saha B; Fang B; Koomen JM; Chellappan SP; Maria-Engler SS; Rix U; Licht JD; Harbour JW; Smalley KSM
Clin Cancer Res; 2019 Sep; 25(18):5686-5701. PubMed ID: 31227503
[TBL] [Abstract][Full Text] [Related]
19. PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.
Rahmani M; Aust MM; Benson EC; Wallace L; Friedberg J; Grant S
Clin Cancer Res; 2014 Sep; 20(18):4849-60. PubMed ID: 25070836
[TBL] [Abstract][Full Text] [Related]
20. BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer.
Fan F; Zhou M; Ye X; Mo Z; Ma Y; Luo L; Liang X; Liu H; Weng Y; Lin M; Liu X; Cai X; Qian C
Transl Oncol; 2021 Feb; 14(2):100961. PubMed ID: 33321427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
